Cargando…

Growth differentiation factor 15 is not associated with glycemic control in patients with type 2 diabetes mellitus treated with metformin: a post-hoc analysis of AIM study

BACKGROUND: Growth differentiation factor 15 (GDF15) was newly discovered to be a promising target of metformin. The study was aimed to investigate the relationship between GDF15 and glycemic control after metformin treatment in patients with type 2 diabetes mellitus. METHODS: The study was a post-h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Fei, Li, Cheng, Wang, Yufei, Lu, Jingyi, Lu, Wei, Zhou, Jian, Yin, Jun, Ma, Xiaojing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588202/ https://www.ncbi.nlm.nih.gov/pubmed/36273168 http://dx.doi.org/10.1186/s12902-022-01176-3

Ejemplares similares

Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure
por: Al‐kuraishy, Hayder M., et al.
Publicado: (2022)

Serum 1,5-Anhydroglucitol to Glycated Albumin Ratio Can Help Early Distinguish Fulminant Type 1 Diabetes Mellitus from Newly Onset Type 1A Diabetes Mellitus
por: Ying, Lingwen, et al.
Publicado: (2020)

Randomized Trial of the Effects of Insulin and Metformin on Myocardial Injury and Stress in Diabetes Mellitus: A Post Hoc Exploratory Analysis
por: Srivastava, Pratyaksh K., et al.
Publicado: (2017)

Timing of Exercise Affects Glycemic Control in Type 2 Diabetes Patients Treated with Metformin
por: Huang, Tao, et al.
Publicado: (2018)

Effect of the combination of mitiglinide and metformin on glycemic control in patients with type 2 diabetes mellitus
por: Cho, Young Min, et al.
Publicado: (2010)

Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy
por: Brath, H, et al.
Publicado: (2016)

Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post‐hoc analysis of concomitant add‐on versus sequential add‐on to metformin and of triple versus dual therapy with metformin
por: Del Prato, Stefano, et al.
Publicado: (2018)

Effects of metformin on disease flares in patients with systemic lupus erythematosus: post hoc analyses from two randomised trials
por: Sun, Fangfang, et al.
Publicado: (2020)

Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study
por: Pusceddu, Sara, et al.
Publicado: (2021)

Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial
por: Cosentino, Francesco, et al.
Publicado: (2022)

Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control
por: Villar, Miriam Méndez-del, et al.
Publicado: (2017)

Effects of Age on Glycemic Control in Patients With Type 2 Diabetes Treated with Insulin Detemir: A Post-Hoc Analysis of the PREDICTIVE™ 303 Study
por: Bhargava, Anuj, et al.
Publicado: (2016)

Glycemic control and neonatal outcomes in women with gestational diabetes mellitus treated using glyburide, metformin, or insulin: a pairwise and network meta-analysis
por: Yu, Dan-Qing, et al.
Publicado: (2021)

Feto-maternal outcomes and Glycemic control in Metformin versus insulin treated Gestational Diabetics
por: Arshad, Rabia, et al.
Publicado: (2017)

Effect of metformin monotherapy and dual or triple concomitant therapy with metformin on glycemic control and lipid profile management of patients with type 2 diabetes mellitus
por: Lin, Yan-Yu, et al.
Publicado: (2022)

Genetic and Phenotypic Factors Affecting Glycemic Response to Metformin Therapy in Patients with Type 2 Diabetes Mellitus
por: Nasykhova, Yulia A., et al.
Publicado: (2022)

Association between growth differentiation factor 15 levels and gestational diabetes mellitus: A combined analysis
por: Lu, Yi-Cheng, et al.
Publicado: (2023)

Abstract 25: Glycemic variability of oral semaglutide versus empagliflozin: A post hoc analysis of PIONEER 2
por: Shabeer, D, et al.
Publicado: (2022)

Effect of combination therapy with repaglinide and metformin hydrochloride on glycemic control in Japanese patients with type 2 diabetes mellitus
por: Kawamori, Ryuzo, et al.
Publicado: (2014)

Metformin improves glycemic variability in adults with type 1 diabetes mellitus: an open-label randomized control trial
por: Zhang, Xiuzhen, et al.
Publicado: (2021)

Leptin and the rs2167270 Polymorphism Are Associated with Glycemic Control in Type Two Diabetes Mellitus Patients on Metformin Therapy
por: Alfaqih, Mahmoud A., et al.
Publicado: (2023)

Effect of Metformin on Testosterone Levels in Male Patients With Type 2 Diabetes Mellitus Treated With Insulin
por: Cai, Tingting, et al.
Publicado: (2021)

Assessment of glycemic control in patients with type 2 diabetes mellitus treated with metformin–sulfonylurea combination: Results of a multicenter, cross-sectional, observational study in Korea
por: Kim, Sin Gon, et al.
Publicado: (2015)

Quantifying the Effect of Metformin Treatment and Dose on Glycemic Control
por: Hirst, Jennifer A., et al.
Publicado: (2012)

Impact of post-procedural glycemic variability on cardiovascular morbidity and mortality after transcatheter aortic valve implantation: a post hoc cohort analysis
por: Besch, Guillaume, et al.
Publicado: (2019)

The association between serum growth differentiation factor 15 levels and lower extremity atherosclerotic disease is independent of body mass index in type 2 diabetes
por: He, Xingxing, et al.
Publicado: (2020)

Circulating selenoprotein P levels predict glucose‐lowering and insulinotropic effects of metformin, but not alogliptin: A post‐hoc analysis
por: Takeshita, Yumie, et al.
Publicado: (2022)

Development of a patient decision aid for type 2 diabetes mellitus for patients not achieving glycemic control on metformin alone
por: Shillington, Alicia C, et al.
Publicado: (2015)

Impact of Glycemic Control and Metformin Use on the Recurrence and Progression of Non-Muscle Invasive Bladder Cancer in Patients with Diabetes Mellitus
por: Ahn, Ji Hoon, et al.
Publicado: (2016)

Effect of Extended Release Niacin on Cardiovascular Events and Kidney Function in Chronic Kidney Disease: A Post-Hoc Analysis of the AIM-HIGH Trial
por: Kalil, Roberto S., et al.
Publicado: (2015)

Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin
por: Tanaka, Atsushi, et al.
Publicado: (2021)

Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis
por: Fu, Haoda, et al.
Publicado: (2015)

PSUN191 Hospital Outcomes of Intensive and Standard Inpatient Glycemic Targets: A Propensity Scored-Matched Post Hoc Analysis of Insulin-Treated Patients with Type 2 Diabetes
por: Fafyman, Maya, et al.
Publicado: (2022)

Veneral Prophylaxis Post Hoc
Publicado: (1913)

AIMing 2 treat atherosclerosis
por: Soehnlein, Oliver, et al.
Publicado: (2022)

Efficacy and Safety of Alirocumab in Japanese Patients with Diabetes Mellitus: Post-hoc Subanalysis of ODYSSEY Japan
por: Teramoto, Tamio, et al.
Publicado: (2019)

Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
por: Husain, Mansoor, et al.
Publicado: (2022)

Metformin in COVID-19: Is There a Role Beyond Glycemic Control?
por: Nagendra, Lakshmi, et al.
Publicado: (2023)

Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials
por: Jódar, Esteban, et al.
Publicado: (2021)

Erratum to: Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis
por: Fu, Haoda, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_adder8lnq2c6ee6f4jt74r21pj